2026 is a year of transition for healthcare and life sciences as the industry moves toward more convenient, patient-centric care. As more firms lean on clinical AI to drive growth in digital health platforms, it is opening up new opportunities for more nimble upstarts to challenge incumbent firms. These advances are occurring amid broad market uncertainty as firms content with unexpectedly low Medicare Advantage reimbursement rates.
In this report, we harness broker research, Tegus expert insights, and company commentary in AlphaSense to explore how the debates below are shaping the healthcare and life sciences landscape in 2026:
- CYTK vs. BMY in oHCM
- 2027 Medicare Advantage Rates
- Aktis Oncology vs. Novartis
- SpyGlass Pharma IPO
- Oral GLP1 Market
- Doximity: Reacceleration Prospects
- Avantor: Turnaround Progress
- uniQure: AMT130 for Huntingtonʼs Disease




